PLAU and neoplasm: For knockdown studies simultaneously targeting uPAR, uPA or MMPs, mostly the MDA-MB-231, ZR751 or non-TNBC cell lines were applied and the combined knockdown approaches led to significant and additive effects regarding reduced malignancy of tumour cells [31–33] corresponding to our results.